Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.55 |
| ▸ | PPARA | Q07869 | 13/20 | 0.55 |
| ▸ | PPARD | Q03181 | 10/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520754 | 0.88 | PPARG (0.70) | PPARGPPARAPPARDACLY | |
| SCHEMBL3524707 | 0.86 | PPARG (0.59) | PPARGPPARAPPARDCYP11B1CYP11B2 | |
| SCHEMBL3526398 | 0.85 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL3523098 | 0.85 | PPARG (0.58) | PPARGPPARAPPARDCYP11B1CYP11B2 | |
| SCHEMBL3521759 | 0.84 | PPARG (0.58) | PPARGPPARAPPARDCYP11B1CYP11B2 | |
| SCHEMBL3528397 | 0.84 | PPARG (0.78) | PPARGPPARAPPARD | |
| SCHEMBL3524268 | 0.84 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL3525614 | 0.83 | PPARG (0.57) | PPARGPPARAPPARD | |
| SCHEMBL3521598 | 0.82 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL3526885 | 0.82 | PPARG (0.73) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436040-B2 | Method of treating conditions involving PPAR-receptors with indole compounds | LABORATOIRES FOURNIER S.A. (FR) | 2013-05-07 | — | — | US | disclosed |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | LABORATORIES FOURNIER S.A. (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7795297-B2 | Indole compounds, method of preparing them and uses thereof | LABORATORIES FOURNIER S.A. (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LIPG, GPR119, IAPP | PPARG 1018/4885PPARA 847/4885PPARD 677/4885 |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | GPR119, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.